ASRI2005-93 A new aspect of reproduction in infertility associated with polcystic ovarian syndrome
Article first published online: 5 AUG 2005
American Journal of Reproductive Immunology
Volume 54, Issue 2, pages 122–123, August 2005
How to Cite
Mehrotra, V. and Saini, P. (2005), ASRI2005-93 A new aspect of reproduction in infertility associated with polcystic ovarian syndrome. American Journal of Reproductive Immunology, 54: 122–123. doi: 10.1111/j.1600-0897.2005.00295_9.x
- Issue published online: 5 AUG 2005
- Article first published online: 5 AUG 2005
- Cited By
Introduction: Polycystic ovarian syndrome (PCOS) is one of the commonest causes of anovulatory infertility presenting with menstrual abnormalities. The common treatment is to ovulate and conceive is Clomiphene citrate but 50% becomes pregnant with first trimester abortion rate high. The aim is for better judgment of efficacy of Clomiphene citrate and recombinant FSH for ovulation induction.
Method: Patients (120) were divided in two groups: treated with Clomiphene citrate and other on recombinant FSH. Ovarian response was monitored and HCG given to trigger ovulation after appropriate follicular development. The prime out come major cumulative pregnancies after undergoing up to 4 treatment cycles. Results: The study showed that aspects of reproduction with pregnancy rate were more in recombinant FSH as compare to clomiphene citrate. Abortion rate was less in recombinant FSH then clomiphene citrate group. The incidences of OHSS were least in both. The main aspects of reproduction after 4-treatment cycle were 45.8% with recombinant FSH and only 11.2% with Clomiphene citrate.
Conclusions: Various RCTs have been done before showing benefits of Gonadotrophins over Clomiphene citrate. Study suggests that recombinant FSH effective alternative of Clomiphene citrate in first line treatment for the reproduction of anovulatory PCOS patients.